Close Menu

NEW YORK (GenomeWeb) – A team led by researchers at St. Jude Children's Research Hospital has conducted an integrated analysis of rhabdomyosarcoma (RMS) samples that involved transcriptomic, epigenomic, proteomic, and phosphoproteomic data, leading them to a number of deregulated pathways.

Through subsequent preclinical testing, the researchers also found the WEE1 kinase to be a promising target for treating high-risk RMS.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Sponsored by

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.